Metrics
1 Record Views
- Title
- 570P Feasibility and biomarker validation of an international randomized phase 3 trial of bria-IMT cell therapy in late stage MBC (Bria-ABC)
- Creators
- S. Hurvitz - University of WashingtonJ. O'Shaughnessy - Oncology, Texas Oncology - Baylor Sammons Cancer Center, Dallas, United States of AmericaC. Nangia - Hoag Memorial Hospital PresbyterianL. Negret - Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, United States of AmericaC. Calfa - Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, United States of AmericaA. Kahn - University of New HavenM. Barve - Mary Crowley Cancer Research CenterR. Shatsky - UC San Diego Health SystemA. Brufsky - UPMC Hillman Cancer CenterR. Zuniga - Department of Medical Oncology & Hematology, New York Cancer and Blood Specialists, New York, United States of AmericaM. Cristofanilli - Weill Cornell MedicineB. Bayer - Clinical Scientist / Operations Associate, BriaCell Therapeutics Corp., Philadelphia, United States of AmericaW. Williams - Clinical Scientist / Operations Associate, BriaCell Therapeutics Corp., Philadelphia, United States of AmericaG. Del Priore - Morehouse School of MedicineS. Chumsri - Mayo Clinic in Florida
- Publication Details
- Annals of oncology, Vol.36, pp.S444-S445
- Publisher
- Elsevier Ltd; AMSTERDAM
- Number of pages
- 2
- Grant note
- BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp.
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991032900560202976